Tag: diabetes drugs
Diabetes Drug Risk: W&L Hopes Faster FDA Publication of Potential Risk Signals for SGLT2 Inhibitors
NEWS: (NEW YORK, N.Y.) National lawfirm Weitz and Luxenberg, P.C., said today it hopes potentially fatal side effects associated with SGLT2 inhibitor drugs will be reported to consumers faster, since people taking these next-generation diabetes medications deserve to be notified of the health dangers shortly after they have been reported to the U.S. Food and Drug Administration (FDA).
Serious Urinary Tract Infections added to SGLT2 Inhibitor Injuries Probe by Weitz & Luxenberg
NEWS: Weitz and Luxenberg, P.C., today announced that the firm has expanded the scope of its investigation into SGLT2 inhibitor drug injuries. SGLT2 inhibitor drugs include Invokana and others listed below. This move will allow the nationally known mass tort law and personal injury firm to focus on cases where people taking SGLT2 inhibitors were hospitalized after developing urosepsis (serious infection of the blood) or pyelonephritis (infection of the kidneys) from SGLT2 inhibitor-associated urinary tract infections.
